ALZHEIMER'S BLOOD TEST COULD BRING HIGHLY ACCURATE DIAGNOSIS INTO EVERYDAY CLINICAL CARE

A real-world study of 1,310 Swedish patients (383 primary care) found PrecivityAD2™ blood biomarker testing (amyloid beta + phosphorylated tau) raised diagnostic accuracy for specialists from 74% to 89%, and for primary care from 65% to 93% (vs ~90% in head-to-head comparisons after results). Physicians changed diagnoses in ~30% of primary care cases and revised clinical management in about half, with negative results increasing ruling-out of Alzheimer’s from 12.9% to 25%. The findings support using accurate blood tests to expand Alzheimer’s diagnostic capability beyond specialist settings, potentially reducing delays and unnecessary referrals.

Analysis

The real economic signal is not the test itself but the workflow shift: primary care can now triage cognitive complaints without sending every patient into a high-cost specialty funnel. That is structurally negative for amyloid PET, lumbar puncture, and memory-clinic bottlenecks, while favoring centralized lab networks and sample logistics businesses that can own the front end of screening. The first-order revenue pool is still likely modest; the bigger prize is routing share and becoming the default gatekeeper for downstream neurology utilization.

Near term, the market may overestimate how quickly a positive blood test converts into drug starts. Clinicians appear willing to use the result to rule out disease, but positive cases still need confirmatory workup and payer acceptance, so the volume uplift to treatment franchises should lag the headline. The more immediate catalyst is guideline/reimbursement adoption over the next 1-3 months; if coverage is narrow or prior auth remains strict, utilization could disappoint even if clinical enthusiasm stays high.

Contrarian view: the consensus is focused on access, but the more investable effect may be diagnostic deflation. Cheaper rule-out testing can compress economics for imaging-heavy diagnostics and specialist consults, which is bearish for PET infrastructure and neutral-to-bearish for hospitals with dementia workups. Falsifiers: if payer policies limit use to specialty settings, if negative-test triage fails to reduce referrals, or if follow-on confirmation rates stay high enough that the test simply adds cost without changing the pathway.

Key Decisions for Investors

• Watchlist, not a trade yet: wait for CMS/private payer coverage language and ALZ guideline adoption before sizing any long in LH or DGX; the upside is routing share, but the thesis fails if utilization stays confined to specialty clinics.
• Small pair trade idea: long LH / short GEHC for 1-3 months if reimbursement momentum builds; LH can monetize draw-and-send workflow, while GEHC faces incremental pressure on amyloid PET demand. Use a tight stop if imaging volumes do not roll over.
• If you want the purest beneficiary, express it via a basket long in large diagnostics labs and CRO-adjacent names rather than the test developer alone; the value accrues to distribution and reimbursement scale, not just assay IP.
• Avoid chasing the Alzheimer’s therapy names on this headline alone; BIIB gets a longer-dated diagnosis tailwind, but near-term upside is capped unless you see confirmatory-testing volume and treatment initiation data improve over the next 1-2 quarters.